Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007189 · ClinicalTrials.gov registry record · Phase 3
Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
A Phase 3 study, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,625
- Enrollment target
NCT00007189 is a Phase 3 study that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 2,625 participants.
The verdict
NCT00007189, a Phase 3 study, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,625 participants
- Enrollment target
Study Summary
The purpose of this trial is to test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline.
Interventions
- DRUG Celecoxib (Celebrex)
- DRUG Naproxen Sodium (Aleve)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,625 participants |
| Start Date | 2001-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00007189
The ClinicalTrials.gov registry entry for NCT00007189 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,625 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Celecoxib (Celebrex) is the first listed.
NCT00007189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00007189 about?
NCT00007189 is a clinical study titled "Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)". The purpose of this trial is to test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline.
What is the current status of trial NCT00007189?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,625 participants. The study started on 2001-01.
What interventions are being tested in trial NCT00007189?
The interventions under investigation include: Celecoxib (Celebrex) (DRUG), Naproxen Sodium (Aleve) (DRUG).
Who is sponsoring clinical trial NCT00007189?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.